Vaxart Secures $25M Equity Financing, Registers 32.9M Shares for Resale

Vaxart, Inc. has entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, securing up to $25 million in committed equity financing. Under this agreement, Vaxart may sell common stock to Lincoln Park, and Lincoln Park may resell up to 32,914,599 shares, including 447,067 commitment shares already issued. The company's common stock was delisted from Nasdaq in November 2025 and now trades on the OTCQX. Vaxart reported $61.0 million in cash as of March 31, 2026, sufficient to fund operations into Q2 2027, and an accumulated deficit of $455.0 million.